Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Non-small Cell Lung Cancer · Epilepsy

Eisai

Eisai Co.,

NovaPharmaNews editorial coverage mentioning Eisai — regulatory, clinical, and market analysis.

Website Investor relations
Tokyo, Japan, JP HQ
41 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Tokyo, Japan, JP
Employees
41
Programs
22
Drugs
31
Patents
0
Official website ↗ All projects Drug pipeline News & analysis

Recent coverage

View all news & analysis →
Intelligence · Coverage

News & analysis

NovaPharmaNews articles mentioning Eisai — regulatory, clinical, and market coverage.

NovaPharmaNews editorial coverage mentioning Eisai — regulatory, clinical, and market analysis.

All News Analysis

1 articles

Biogen and Eisai expand Leqembi access with subcutaneous maintenance dosing
High impact NewsAlzheimer's diseaseJun 7, 2026

Biogen and Eisai expand Leqembi access with subcutaneous maintenance dosing

Alzheimer's disease · 5 min

Biogen and Eisai have expanded LEQEMBI access in the U.S. with subcutaneous maintenance dosing, following FDA approval of the BLA in August 2025. The move could improve convenience, reduce infusion-related burden, and shape investor expectations for Eisai and Biogen stock.

Dr. Sarah Mitchell

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.